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ABSTRACT
INTRODUCTION: Herpes zoster and its sequelae can have a serious impact on quality of life, particu-
larly in the elderly. The duration and severity of herpes zoster symptoms can be reduced with antiviral 
treatment. Early treatment is most effective. 
AIM: To identify how soon after onset of herpes zoster symptoms adults presented to a suburban Dun-
edin general practice and to describe which patients received antiviral treatment. 
METHODS: Adult herpes zoster cases were identified from a large suburban general practice from 2004 
to 2009. Duration of symptoms at presentation and antiviral prescription were identified from medical 
records and described by patient characteristics. 
RESULTS: We identified 278 incident cases. Approximately one-third presented within three days 
of symptoms, one-third after three days, and in one-third of cases the duration of symptoms was not 
documented. A higher percentage of patients with ophthalmic herpes zoster presented within three days 
(45%), while a lower percentage of men (24%) and patients from the lowest socioeconomic quintile (25%) 
presented within three days. Most incident cases received antiviral treatment. A higher percentage of pa-
tients with ophthalmic herpes zoster and patients who presented within three days of symptoms received 
antiviral treatment. Some patients who presented after seven days of symptoms also received treatment. 
Antiviral prescribing did not increase with patient age. 
DISCUSSION: Despite many adults with acute herpes zoster presenting after three days of symptoms, 
most received antiviral treatment. It is not known why many presented late. It is not known whether late 
treatment is effective.
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Introduction
Herpes zoster is generally experienced as a pain-
ful, vesicular rash with a unilateral dermatomal 
distribution. The rash is often preceded by pro-
dromal symptoms, including pain in the region of 
the affected sensory nerve, fever and malaise. 
Herpes zoster is caused by reactivation of the 
varicella zoster virus that has remained dormant 
in a cranial nerve or dorsal root ganglion since a 
primary infection (chicken pox). Precise triggers 
for reactivation are unknown, although herpes 
zoster is more common with increasing age and 
with immune-compromise.1 The annual rate 
of herpes zoster is about 3 to 4 cases per 1000, 
roughly doubling every decade after the age of 50 
years.1–6 Studies suggest the incidence of herpes 
zoster is increasing.1 Vaccination has been shown 
to reduce the incidence of both herpes zoster 
and its complications, and is recommended for 
patients 60 years or older.7,8
Herpes zoster and its complications can have a 
serious impact on quality of life, and impose an 
economic burden on the health service and on 
society. It is estimated that herpes zoster costs 
the Australian health system about A$32.8 
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million per year.9 The burden of herpes zoster 
in New Zealand is not known; herpes zoster is 
not mentioned in the recent Ministry of Health 
burden of diseases study.10 
Early antiviral treatment (within three days of 
onset of symptoms) has been shown to hasten 
rash healing and decrease the severity and dura-
tion of acute pain.1,11,12 Antiviral treatment is 
generally recommended for those at highest risk 
of complications from herpes zoster, including 
the elderly, the immune-compromised, and those 
with severe symptoms or eye or facial involve-
ment.1,4,11,13 Other patients might also benefit 
from antiviral treatment, but their risk of compli-
cations is lower. 
Valacyclovir and famciclovir are the preferred an-
tiviral drugs because of ease of dosing and higher 
levels of antiviral drug activity.1,11 Acyclovir is 
less effective for reducing herpes zoster pain and 
must be taken five times a day, but it is well toler-
ated, generally safe, and relatively cheap.14 In New 
Zealand, acyclovir is the only fully funded anti-
viral for use in general practice—valacyclovir is 
funded with special authority, and famciclovir is 
not funded. A recent Cochrane review found that 
oral acyclovir does not significantly reduce the 
incidence of post-herpetic neuralgia (PHN), and 
that there is insufficient evidence to determine 
whether valacyclovir and famciclovir prevent 
PHN.15 Despite early antiviral treatment, many 
patients experience persistent pain and long-term 
reduction in health-related quality of life.16
While early treatment is most effective, in 
clinical practice there are many barriers to early 
presentation and treatment, including delays in 
recognising the significance of prodromal symp-
toms, delays in making an appointment (perhaps 
because of cost or transport barriers), and delays 
in getting an appointment (especially if symp-
toms start on a Friday). There may be further de-
lays in receiving antiviral treatment as prodromal 
pain may be misdiagnosed. 
Patients may benefit when antiviral treatment is 
started after three days, but the efficacy of later 
treatment has not been systematically studied 
and there is no clear guidance on how to manage 
patients who present later. The controlled clinical 
WHAT GAP THIS FILLS
What we already know: Herpes zoster causes considerable suffering and 
imposes an increasing burden on the health system. The duration and sever-
ity of herpes zoster symptoms can be reduced with antiviral treatment. Early 
treatment is most effective. It is not known how soon after onset of symp-
toms patients with herpes zoster present to general practice in New Zealand, 
nor which patients receive antiviral treatment.
What this study adds: In this study of acute herpes zoster in a single, 
large New Zealand general practice, many patients presented after three 
days of symptoms but most received antiviral treatment. 
trials of antiviral treatment have started treatment 
within three days of onset of symptoms—an arbi-
trary inclusion criterion that does not necessarily 
reflect the cessation of viral replication.11 The 
National Institute for Health and Care Excellence 
(NICE) recommends antiviral treatment up to one 
week after rash onset for those at higher risk of se-
vere herpes zoster or complications;13 other experts 
Patients may benefit when antiviral treatment is 
started after three days, but the efficacy of later 
treatment has not been systematically studied 
and there is no clear guidance on how to manage 
patients who present later
recommend initiating treatment after three days 
of symptoms if new skin lesions are still appear-
ing, if complications are present, or if there is ad-
vanced age or severe pain.1,4,11 The manufacturer’s 
acyclovir datasheet on the Medsafe (New Zealand 
Medicines and Medical Devices Safety Author-
ity) website recommends treatment ‘as soon as 
possible after the onset of infection’ to reduce the 
‘acute symptoms and rash, for reduction of zoster-
associated pain and for reduction of the incidence 
and duration of post-herpetic neuralgia’.17 
There is no New Zealand research showing how 
soon after onset of symptoms patients with 
acute herpes zoster present in general practice, or 
which patients receive antiviral therapy. The aim 
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set of herpes zoster symptoms adults presented to 
their general practitioner in a suburban Dunedin 
general practice, and to describe which patients 
received antiviral treatment. 
Methods 
Data source
The study utilised the electronic medical records 
of a large suburban Dunedin general practice. The 
general practice uses the Medtech32 electronic 
practice management system (PMS). It is the poli-
cy of the general practice to code all diagnoses.
The general practice had 15 500 registered 
patients on average over the study years; 8% of 
the practice population were Maori or Pacific, the 
remainder mostly European; 48% were male and 
52% female. Eight percent of the practice popula-
tion were over 65 years, compared to 14% for the 
Otago District Health Board (DHB) region and 
12% for New Zealand as a whole in the 2006 cen-
sus. The breakdown of the practice population by 
the NZDep2006 index (an index of socio  economic 
deprivation for each meshblock based on the 2006 
census, where quintile 5 denotes the most socio-
economic deprivation and quintile 1 the least) is as 
follows: quintile 1 (18%), quintile 2 (23%), quin-
tile 3 (23%), quintile 4 (20%), and quintile 5 (16%). 
Incident zoster cases
LH liaised with the practice nurse who identi-
fied all patients with a new diagnostic Read code 
of herpes zoster or shingles between 1 January 
2004 and 31 December 2009. We included data 
for all patients aged 18 years or older residing in 
their own home (i.e. those not in residential care), 
with a presenting complaint consistent with acute 
herpes zoster (i.e. we excluded those who pre-
sented with complications of herpes zoster, such 
as post-herpetic neuralgia or who were incorrectly 
coded). We excluded the records of patients living 
in residential care because we wanted to focus on 
herpes zoster in the community, and because the 
daily records of patients living in residential care 
settings were paper-based rather than electronic. 
We obtained a printout of de-identified medical 
records for all incident cases. KR searched the 
daily record for days of symptoms at presenta-
tion (less than three days, between three and 
seven days, and more than seven days), affected 
dermatome (ophthalmic, other cervical, tho-
racic, lumbosacral), and antiviral prescription 
(yes or no), and entered these data onto an Excel 
spreadsheet, along with patient age at presenta-
tion, gender, socioeconomic quintile, pre-existing 
conditions and medications. ‘Days of symptoms 
at presentation’ was taken as that recorded in the 
daily record by the treating doctor. If, for exam-
ple, the daily record stated ‘painful rash three 
days R upper thoracic region’, the case was coded 
as presenting between three and seven days, and 
the affected dermatome as thoracic.
Data analysis
We described duration of symptoms at presenta-
tion by patient characteristics, including age, sex, 
socioeconomic quintile and affected dermatome. 
We described antiviral prescription by patient 
characteristics and by duration of symptoms at 
presentation. No statistical analyses were con-
ducted as the study was insufficiently powered.
None of the authors work or are patients at the 
general practice that provided the study data. 
Ethical approval for this study was provided by 
the Lower South Regional Ethics Committee, 
(Ref. LRS/10/EXP/020). 
Results 
Adults with acute herpes zoster 
We identified 353 patients with a new diagno-
sis of herpes zoster during the six study years 
(2004–2009). After excluding cases that did not 
fit the inclusion criteria, there were 278 adult 
acute herpes zoster cases remaining. Most exclu-
sions were for age under 18 years, while a few 
were for a diagnosis other than acute herpes zos-
ter. Incident cases were aged up to 98 years, but 
most were younger than 65 years (75%). There 
were more women than men in our sample (58%). 
Duration of symptoms at presentation 
Table 1 summarises duration of symptoms at 
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of incident cases presented within three days 
of symptoms (92; 33%). A higher percentage of 
women (40%) than men (24%) presented within 
three days of symptoms. A higher percentage of 
patients with ophthalmic herpes zoster presented 
within three days (45%) than those with other 
dermatomal involvement, with the lowest per-
centage of early presentations for thoracic herpes 
zoster (28%). A lower percentage of patients 
from quintile 5 (most deprived) presented within 
three days of symptoms (25%) compared to other 
quintile groups. Age did not influence duration 
of symptoms at presentation. 
Antiviral treatment
Table 2 summarises antiviral treatment by 
patient characteristics. Most of the 278 incident 
cases received antiviral treatment (82%). Acyclo-
vir was the only antiviral prescribed. A higher 
percentage of patients with ophthalmic herpes 
zoster received antiviral treatment (97%) than 
those with other dermatomal involvement, with 
patients with thoracic herpes zoster least likely 
to receive antiviral treatment (75% of patients 
treated with antivirals). A higher percentage of 
patients presenting within three days of symp-
toms received antiviral treatment (96%), but 
almost one-third of patients who presented after 
seven days of symptoms also received antiviral 
treatment (32%). Antiviral prescribing did not 
increase with age.
Discussion 
This study presents a single general practice audit 
assessing how soon after onset of symptoms 
adults with acute herpes zoster present to their 
general practitioner, and describing antiviral 
prescribing patterns. Previous research findings 
suggest 50–75% of patients present within three 
days of herpes zoster symptoms.6,16 In our study, 
approximately one-third of incident cases pre-
sented within three days of symptoms, one-third 
presented after three days, and in one-third, the 
duration of symptoms was not documented. A 
Table 1. Duration of herpes zoster symptoms at presentation by patient characteristics (N=278)
Patient characteristic n (%)
Duration of symptoms at presentation
n (%)
Less than 
3 days
3–7  
days
More than 
7 days
Not  
stated
Sex
Male  117 (42%) 28 (24%) 30 (26%) 12 (10%) 47 (40%)
Female  161 (58%) 64 (40%) 42 (26%) 13 (8%) 42 (26%)
Age group 
(years)
18–49  126 (45%) 43 (34%) 37 (29%) 11 (9%) 35 (28%)
50–64  82 (30%) 27 (33%) 21 (26%) 7 (8%) 27 (33%)
65+  70 (25%) 22 (31%) 16 (23%) 5 (7%) 27 (39%)
Dermatome
Ophthalmic  31 (11%) 14 (45%) 5 (16%) 2 (7%) 10 (32%)
Cervical—ex 
ophthalmic
75 (27%) 29 (39%) 15 (20%) 3 (4%) 28 (37%)
Thoracic  129 (46%) 36 (28%) 44 (34%) 14 (11%) 35 (27%)
Lumbosacral  38 (14%) 11 (29%) 13 (34%) 3 (8%) 11 (29%)
Not stated  5 (2%) 1 (20%) 1 (20%) 1 (20%) 2 (40%)
Socioeconomic 
deprivation 
quintile
Quintile 1 64 (23%) 22 (34%) 15 (23%) 6 (9%) 21 (33%)
Quintile 2 55 (20%) 17 (31%) 19 (35%) 3 (6%) 16 (29%)
Quintile 3 69 (25%) 23 (33%) 14 (20%) 4 (6%) 28 (41%)
Quintile 4 46 (17%) 16 (35%) 12 (26%) 5 (11%) 13 (28%)
Quintile 5 44 (16%) 11 (25%) 15 (34%) 5 (11%) 13 (30%)
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lower percentage of men (24%) than women (40%) 
presented within three days. It is not known why 
many patients in our study presented after three 
days. A lower percentage of patients from quin-
tile 5 (25%) presented within three days, hinting 
that cost may be a factor. While a higher percent-
age of patients with ophthalmic zoster presented 
within three days (45%), it is concerning, given 
the potentially serious nature of ophthalmic 
herpes zoster, that nearly one-quarter of patients 
with ophthalmic herpes zoster presented after 
three days of symptoms, although numbers were 
small (7; 23%). 
Despite many patients presenting after three days 
of symptoms, most patients in our study received 
antiviral treatment (82%). Previous research has 
found between 22% and 85% of adults receive 
antiviral treatment, with prescribing increasing 
with age.9,16,18,19 Antiviral prescribing did not 
increase with age in our study. We found that a 
higher percentage of patients with ophthalmic 
Table 2. Proportion of adults with herpes zoster receiving antiviral treatment by patient 
characteristics and duration of symptoms at presentation
Patient characteristic n
Received antiviral treatment 
n (%)
Sex
Male  117 92 (79%)
Female  161 135 (84%)
Age group (years)
18–49  126 105 (83%)
50–64  82 65 (79%)
65+  70 57 (81%)
Dermatome
Ophthalmic  31 30 (97%)
Cervical—other 78 67 (86%)
Thoracic  122 91 (75%)
Lumbosacral  38 31 (82%)
Not stated  9 8 (88 %)
Socioeconomic 
deprivation 
quintile
Quintile 1 64 52 (81%)
Quintile 2 55 43 (78%)
Quintile 3 69 58 (84%)
Quintile 4 46 39 (85%)
Quintile 5 44 35 (80%)
Duration of 
symptoms at 
presentation 
(days)
Less than 3  92 88 (96%)
3–7  72 57 (79%)
More than 7  25 8 (32%)
Not stated  89 74 (83%)
Total 278 227 (82%)
herpes zoster (97%) received antiviral treatment, 
as did those who presented within three days 
of symptoms (96%). We also found that approxi-
mately one-third of patients who presented after 
seven days of symptoms received antiviral treat-
ment, which is surprising since it is not known 
whether treatment at this late stage is effective; 
it should be noted, however, that numbers were 
small (8; 32%). 
The strengths of this study are that it is based 
in a large, fully computerised general practice 
that codes diagnoses; the dataset provided useful 
electronic data, including detailed daily records; 
and the analyses answered the two research ques-
tions. However, the study suffers from a number 
of limitations. The dataset was small, the clinical 
records incomplete (one-third lacked information 
about the duration of herpes zoster symptoms), 
and we may have missed incident herpes zoster 
cases that were not classified, all potentially 
introducing bias. Doctors may be more likely 
to classify herpes zoster cases when prescribing 
antiviral therapy because of the way the practice 
management system is set up, possibly explaining 
our high antiviral prescribing rate. We excluded 
patients in residential care, potentially explaining 
why the elderly were under-represented in our 
study (75% of incident cases were younger than 
65 years). 
Despite these limitations, the study provides 
new information about how soon after onset of 
symptoms patients with acute herpes zoster pre-
sented to their general practitioner in a suburban 
New Zealand general practice, and which patients 
received antiviral treatment. 
The study found that most adults with acute 
herpes zoster received antiviral treatment, despite 
many presenting after three days of symptoms. 
Further work is needed to confirm our findings, 
and to determine whether the high antiviral 
prescribing rate is indicative of prescribing in the 
wider New Zealand general practice context. Fur-
ther work is also needed to understand the rea-
sons for late presentation, and to learn how best 
to manage herpes zoster presenting after three 
days of symptoms. Since acyclovir is now known 
not to prevent PHN, the acyclovir datasheet17 
should be updated to remove this indication. VOLUME 6 • NUMBER 2 • JUNE 2014  JOURNAL OF PRIMARY HEALTH CARE 113
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